Trial Profile
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Single Center Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2018
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 10 Sep 2018 Status changed from not yet recruiting to completed.
- 16 Mar 2013 New trial record